Remarkable 8-Year Survival in Advanced Liver Cancer Patient
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a pioneering biotechnology firm, has exciting news regarding its innovative treatment for advanced liver cancer. Recently, a patient enrolled in Can-Fite’s compassionate use program exhibited an astounding overall survival time of eight years after receiving the company’s Namodenoson drug. This breakthrough not only highlights the potential of Namodenoson but also enhances the understanding of treating Hepatocellular Carcinoma (HCC).
Significant Patient Outcomes and Treatment Overview
The patient, who formerly grappled with advanced liver cancer, participated in Can-Fite’s Phase II clinical study, where they have continually received Namodenoson. Remarkably, they have not only achieved an eight-year survival milestone but also experienced a complete response characterized by the disappearance of ascites, preserved liver functionality, and an enhanced quality of life. This case represents a long-term success story for the treatment of liver cancer.
Phase III Clinical Study Initiatives
Can-Fite is actively recruiting participants for a pivotal Phase III clinical trial across various regions, including Europe and the U.S. This clinical study aims to evaluate Namodenoson’s efficacy as a second or third-line treatment option for advanced liver cancer. Patients will take Namodenoson orally, twice per day, as part of this trial. The study protocol has gained approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), emphasizing the rigorous standards the treatment must meet.
Recognitions and Existing Studies on Namodenoson
Namodenoson holds Orphan Drug status from both the FDA and EMA, along with Fast Track status from the FDA for the treatment of HCC. Furthermore, a compassionate use program has been successfully implemented in Israel and Romania. The ongoing positive experiences associated with Namodenoson are encouraging for future trials and implementations.
Expert Insights on Namodenoson
According to Prof. Salomon Stemmer, a noted expert at the Institute of Oncology, Rabin Medical Center in Israel, Namodenoson’s safety profile and anticancer properties make for strong expectations for future patient enrollments in the Phase III study. Many hope to see results akin to the remarkable eight-year response experienced by the current patient. The unique mechanism of action for Namodenoson allows it to specifically target tumor cells while safeguarding healthy liver tissues, which is a pivotal consideration for its clinical potential.
The Landscape of Liver Cancer Treatment
Liver cancer remains a global health challenge, with over 700,000 fatalities each year, as reported by the American Cancer Society. The aggressive nature of HCC often correlates with low survival rates, reflecting the urgent need for effective therapies. As new treatment modalities such as Namodenoson continue to emerge, projections indicate that the market for HCC therapies could soar to approximately $6.1 billion by 2027 in G8 countries.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. aims to revolutionize the treatment landscape for cancer and inflammatory diseases through its clinical-stage drug development. The company’s leading candidate, Namodenoson, is presently under investigation in several trials, including those for MASH and pancreatic cancer, positioning Can-Fite at the forefront of innovation in therapeutic solutions. Additional candidates like Piclidenoson provide promising results in conditions such as psoriasis, further accentuating Can-Fite's broad therapeutic focus.
Contact and Additional Information
If you want to learn more about Can-Fite BioPharma and their groundbreaking work in the realm of cancer treatment, feel free to reach out to their team:
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Frequently Asked Questions
What is Namodenoson?
Namodenoson is a small orally bioavailable drug tailored for treating hepatocellular carcinoma, binding to the A3 adenosine receptor with high affinity.
How does Namodenoson differ from traditional treatments?
Namodenoson selectively targets cancer cells while protecting healthy liver cells, leading to a favorable safety profile.
What recent developments have occurred regarding Can-Fite’s treatments?
An exceptional case of a patient surviving eight years after treatment with Namodenoson highlights its potential effectiveness in managing advanced liver cancer.
What types of studies is Can-Fite currently conducting?
Can-Fite is conducting a pivotal Phase III clinical trial for Namodenoson as a treatment for advanced HCC while continuing to explore other therapeutic avenues.
How can I stay updated on Can-Fite’s research?
Follow their official communications and reports for the latest updates on research, clinical trials, and drug developments.
